company background image
CRIS

Curis NasdaqGM:CRIS Stock Report

Last Price

US$0.78

Market Cap

US$75.2m

7D

0.06%

1Y

-74.8%

Updated

04 Feb, 2023

Data

Company Financials +

CRIS Stock Overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.

CRIS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Curis, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Curis
Historical stock prices
Current Share PriceUS$0.78
52 Week HighUS$3.76
52 Week LowUS$0.47
Beta2.87
1 Month Change27.87%
3 Month Change-0.40%
1 Year Change-74.84%
3 Year Change-46.58%
5 Year Change-69.92%
Change since IPO-99.36%

Recent News & Updates

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Jan 02
Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Recent updates

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Jan 02
Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Sep 16
Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28
Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04
Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29
We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19
Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17
Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

Dec 08

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Dec 03
What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Curis, National Cancer Institute in development pact for anti-cancer agent

Nov 11

Shareholder Returns

CRISUS BiotechsUS Market
7D0.06%-0.8%1.7%
1Y-74.8%4.4%-9.6%

Return vs Industry: CRIS underperformed the US Biotechs industry which returned 4.5% over the past year.

Return vs Market: CRIS underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is CRIS's price volatile compared to industry and market?
CRIS volatility
CRIS Average Weekly Movement12.3%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CRIS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CRIS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200060Jim Dentzerhttps://www.curis.com

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate.

Curis, Inc. Fundamentals Summary

How do Curis's earnings and revenue compare to its market cap?
CRIS fundamental statistics
Market CapUS$75.19m
Earnings (TTM)-US$58.96m
Revenue (TTM)US$10.41m

7.2x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRIS income statement (TTM)
RevenueUS$10.41m
Cost of RevenueUS$35.98m
Gross Profit-US$25.57m
Other ExpensesUS$33.39m
Earnings-US$58.96m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.61
Gross Margin-245.63%
Net Profit Margin-566.41%
Debt/Equity Ratio0%

How did CRIS perform over the long term?

See historical performance and comparison